BPD
MCID: BRN056
MIFTS: 57

Bronchopulmonary Dysplasia (BPD)

Categories: Fetal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Bronchopulmonary Dysplasia

MalaCards integrated aliases for Bronchopulmonary Dysplasia:

Name: Bronchopulmonary Dysplasia 52 58 54 37 62 71
Bpd 52 58

Characteristics:

Orphanet epidemiological data:

58
bronchopulmonary dysplasia
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Infancy,Neonatal; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare respiratory diseases
Developmental anomalies during embryogenesis


External Ids:

MESH via Orphanet 44 D001997
ICD10 via Orphanet 33 P27.1
UMLS via Orphanet 72 C0006287
Orphanet 58 ORPHA70589
UMLS 71 C0006287

Summaries for Bronchopulmonary Dysplasia

PubMed Health : 62 About bronchopulmonary dysplasia: Bronchopulmonary (BRONG-ko-PUL-mo-NAR-e) dysplasia (dis-PLA-ze-ah), or BPD, is a serious lung condition that affects infants. BPD mostly affects premature infants who need oxygen therapy (oxygen given through nasal prongs, a mask, or a breathing tube). Most infants who develop BPD are born more than 10 weeks before their due dates, weigh less than 2 pounds (about 1,000 grams) at birth, and have breathing problems. Infections that occur before or shortly after birth also can contribute to BPD. Some infants who have BPD may need long-term breathing support from nasal continuous positive airway pressure (NCPAP) machines or ventilators.

MalaCards based summary : Bronchopulmonary Dysplasia, also known as bpd, is related to bronchial disease and cerebral palsy. An important gene associated with Bronchopulmonary Dysplasia is SFTPB (Surfactant Protein B), and among its related pathways/superpathways are Innate Immune System and NF-KappaB Family Pathway. The drugs Procaterol and Budesonide have been mentioned in the context of this disorder. Affiliated tissues include Lung, and related phenotypes are emphysema and cough

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 70589 Definition Bronchopulmonary dysplasia is a chronic respiratory disease that results from complications related to lung injury during the treatment of infant acute respiratory distress syndrome (see these terms) in low-birth-weight premature infants or from abnormal lung development in older infants. Clinical signs are tachypnea, tachycardia and signs of respiratory distress such as intercostal recession, grunting and nasal flaring. Visit the Orphanet disease page for more resources.

Wikipedia : 74 Bronchopulmonary dysplasia (BPD; formerly chronic lung disease of infancy) is a chronic lung disease in... more...

Related Diseases for Bronchopulmonary Dysplasia

Diseases related to Bronchopulmonary Dysplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 283, show less)
# Related Disease Score Top Affiliating Genes
1 bronchial disease 31.9 RNASE3 ELANE CXCL8
2 cerebral palsy 30.9 TIMP1 SOD1 CXCL8
3 gastroesophageal reflux 30.7 IL1RN ELANE CXCL8
4 bronchiolitis 30.7 SCGB1A1 RNASE3 CXCL8
5 neonatal respiratory failure 30.7 SFTPB SCGB1A1
6 pulmonary edema 30.6 SCGB1A1 FGF7 CXCL8
7 newborn respiratory distress syndrome 30.6 SFTPB SCGB1A1 FGF7 ELANE CXCL8
8 chorioamnionitis 30.5 IL1RN FLT1 ELANE CXCL8
9 pulmonary fibrosis 30.3 TIMP1 FGF7 ELANE CXCL8
10 interstitial lung disease 30.2 TIMP1 SFTPB CXCL8
11 bronchitis 30.2 RNASE3 ELANE CXCL8
12 bronchiolitis obliterans 30.1 TIMP1 SCGB1A1 CXCL8
13 pre-eclampsia 30.1 SOD1 SELL FLT1 CXCL8
14 bacterial infectious disease 30.0 SELL IL1RN ELANE CXCL8
15 bacterial sepsis 30.0 IL1RN ELANE CXCL8
16 adult respiratory distress syndrome 30.0 SFTPB FGF7 ELANE CXCL8
17 allergic asthma 30.0 SCGB1A1 RNASE3 CXCL8
18 diaphragmatic hernia, congenital 29.9 SFTPB FGF7 FGF10
19 rhinitis 29.8 SCGB1A1 RNASE3 CXCL8
20 pneumonia 29.8 SFTPB SELL SCGB1A1 IL1RN ELANE CXCL8
21 gastroenteritis 29.8 RNASE3 IL1RN CXCL8
22 extrinsic allergic alveolitis 29.7 SOD1 SELL ELANE CXCL8
23 pulmonary emphysema 29.6 TIMP1 FGF7 ELANE CXCL8
24 lung disease 29.5 TXN SOD1 SFTPB SCGB1A1 RNASE3 FGF7
25 proteasome-associated autoinflammatory syndrome 1 29.5 SELL RNASE3 IL1RN ELANE CXCL8
26 otitis media 29.4 RNASE3 IL1RN ELANE CXCL8
27 allergic rhinitis 29.4 SCGB1A1 RNASE3 CXCL8
28 respiratory failure 29.3 TIMP1 SOD1 SFTPB SCGB1A1 RNASE3 IL1RN
29 cataract 28.9 TXN TIMP1 SOD1 IL1RN CXCL8
30 pulmonary disease, chronic obstructive 28.7 TXN TIMP1 SFTPB SCGB1A1 RNASE3 ELANE
31 pulmonary fibrosis, idiopathic 28.6 TIMP1 SFTPB SCGB1A1 IL1RN FGF7 ELANE
32 asthma 28.5 TIMP1 SELL SCGB1A1 RNASE3 IL1RN ELANE
33 borderline personality disorder 11.8
34 pulmonary hypertension, neonatal 11.3
35 pulmonary hypertension 10.9
36 personality disorder 10.9
37 patent ductus arteriosus 1 10.9
38 exudative vitreoretinopathy 1 10.7
39 respiratory distress syndrome in premature infants 10.7
40 enterocolitis 10.6
41 perinatal necrotizing enterocolitis 10.6
42 periventricular leukomalacia 10.5
43 vascular disease 10.5
44 pneumothorax 10.5
45 avoidant personality disorder 10.5
46 pouchitis 10.4 IL1RN CXCL8
47 interstitial emphysema 10.4
48 toxicodendron dermatitis 10.4 SELL CXCL8
49 paraquat lung 10.4 SFTPB SCGB1A1
50 pustulosis of palm and sole 10.4 IL1RN CXCL8
51 toxic pneumonitis 10.3 SFTPB SCGB1A1
52 hypercarotenemia and vitamin a deficiency, autosomal dominant 10.3
53 keratomalacia 10.3
54 sapho syndrome 10.3 IL1RN CXCL8
55 cardiac rupture 10.3 ELANE CXCL8
56 yemenite deaf-blind hypopigmentation syndrome 10.3
57 rickets 10.3
58 pasteurellosis 10.3 ELANE CXCL8
59 pulmonary hypertension, primary, 1 10.3
60 sudden infant death syndrome 10.3
61 tracheomalacia 10.3
62 47,xyy 10.3
63 cytokine deficiency 10.3
64 48,xyyy 10.3
65 pulmonary vein stenosis 10.3
66 attention deficit-hyperactivity disorder 10.2
67 anxiety 10.2
68 intestinal perforation 10.2
69 tricuspid valve insufficiency 10.2
70 mid-dermal elastolysis 10.2 TIMP1 ELANE
71 cryptogenic organizing pneumonia 10.2 TIMP1 CXCL8
72 idiopathic interstitial pneumonia 10.2 SFTPB ELANE CXCL8
73 pleurisy 10.2 SELL IL1RN CXCL8
74 brucellosis 10.2 SELL IL1RN CXCL8
75 meconium aspiration syndrome 10.2 SFTPB SCGB1A1 CXCL8
76 bronchomalacia 10.2
77 branchiootic syndrome 1 10.2
78 funisitis 10.2
79 hydrocephalus 10.2
80 hypertrophic cardiomyopathy 10.2
81 heart septal defect 10.2
82 bronchiectasis 10.2
83 tracheobronchomalacia 10.2
84 cytomegalovirus infection 10.2
85 periodic fever, familial, autosomal dominant 10.2 IL1RN ELANE CXCL8
86 breast cancer 10.2
87 major affective disorder 8 10.2
88 major affective disorder 9 10.2
89 bipolar disorder 10.2
90 fibrosarcoma 10.2
91 erysipelas 10.2 SOD1 IL1RN ELANE
92 arthus reaction 10.1 SELL ELANE
93 atrial standstill 1 10.1
94 hypertriglyceridemia, familial 10.1
95 ige responsiveness, atopic 10.1
96 bone disease 10.1
97 anemia of prematurity 10.1
98 cholestasis 10.1
99 eclampsia 10.1
100 atrial heart septal defect 10.1
101 pulmonary immaturity 10.1
102 apnea of prematurity 10.1
103 aspergillosis 10.1 IL1RN ELANE CXCL8
104 wells syndrome 10.1 RNASE3 CXCL8
105 acute pancreatitis 10.1 IL1RN ELANE CXCL8
106 giant papillary conjunctivitis 10.1 RNASE3 CXCL8
107 stomatitis 10.1 IL1RN FGF7 CXCL8
108 sexual sadism 10.1
109 sexual masochism 10.1
110 mental depression 10.1
111 rhabdomyosarcoma 10.1
112 depression 10.1
113 elephantiasis 10.1 RNASE3 ELANE
114 chronic conjunctivitis 10.1 RNASE3 CXCL8
115 hair whorl 10.1
116 cystic fibrosis 10.1
117 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.1
118 body mass index quantitative trait locus 1 10.1
119 preterm premature rupture of the membranes 10.1
120 cyanosis, transient neonatal 10.1
121 muscle hypertrophy 10.1
122 chlamydia 10.1
123 hemosiderosis 10.1
124 oligohydramnios 10.1
125 placenta disease 10.1
126 respiratory distress syndrome, infant 10.1
127 hypoxia 10.1
128 specific language disorder 10.1
129 parenteral nutrition-associated cholestasis 10.1
130 gingival disease 10.1 TIMP1 ELANE CXCL8
131 conjunctival disease 10.0 RNASE3 IL1RN CXCL8
132 relapsing-remitting multiple sclerosis 10.0 TIMP1 IL1RN CXCL8
133 gingivitis 10.0 TIMP1 ELANE CXCL8
134 conjunctivochalasis 10.0 TIMP1 CXCL8
135 felty syndrome 10.0 ELANE CXCL8
136 chronic granulomatous disease 10.0 SOD1 ELANE CXCL8
137 clear cell acanthoma 10.0 FGF7 FGF10
138 acanthoma 10.0 FGF7 FGF10
139 venous insufficiency 10.0 TIMP1 SELL ELANE
140 fibrosis of extraocular muscles, congenital, 1 10.0
141 strabismus 10.0
142 sandhoff disease 10.0
143 insulin-like growth factor i 10.0
144 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.0
145 lung cancer susceptibility 3 10.0
146 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.0
147 chorea, childhood-onset, with psychomotor retardation 10.0
148 sleep apnea 10.0
149 porencephaly 10.0
150 inguinal hernia 10.0
151 microcephaly 10.0
152 bronchopneumonia 10.0
153 nephrocalcinosis 10.0
154 quadriplegia 10.0
155 choreatic disease 10.0
156 severe pre-eclampsia 10.0
157 hypothyroidism 10.0
158 dermatitis 10.0
159 hypokalemia 10.0
160 neurotic disorder 10.0
161 influenza 10.0
162 mechanical strabismus 10.0
163 refractive error 10.0
164 haemophilus influenzae 10.0
165 periodontal ehlers-danlos syndrome 10.0
166 stenotrophomonas maltophilia infection 10.0
167 gingival overgrowth 10.0 TIMP1 FGF7 CXCL8
168 pneumoconiosis 10.0 SOD1 SCGB1A1 IL1RN CXCL8
169 kawasaki disease 10.0 TIMP1 SELL ELANE
170 allergic hypersensitivity disease 9.9 SELL RNASE3 CXCL8
171 bacterial pneumonia 9.9 SFTPB SCGB1A1 ELANE CXCL8
172 alcohol dependence 9.9
173 optic atrophy with or without deafness, ophthalmoplegia, myopathy, ataxia, and neuropathy 9.9
174 ovarian cancer 9.9
175 prader-willi syndrome 9.9
176 chondrosarcoma 9.9
177 macular degeneration, age-related, 1 9.9
178 acromelic frontonasal dysostosis 9.9
179 bulimia nervosa 9.9
180 major depressive disorder 9.9
181 leptin deficiency or dysfunction 9.9
182 aspiration pneumonia 9.9
183 alexithymia 9.9
184 conduct disorder 9.9
185 post-traumatic stress disorder 9.9
186 substance abuse 9.9
187 mood disorder 9.9
188 acute stress disorder 9.9
189 eating disorder 9.9
190 chronic pain 9.9
191 neonatal hypoxic and ischemic brain injury 9.9
192 adult acute respiratory distress syndrome 9.9
193 aplasia of lacrimal and salivary glands 9.9 FGF7 FGF10
194 diabetes mellitus, type i 9.9 SELL RBP4 IL1RN CXCL8
195 periodontitis 9.8 TIMP1 IL1RN ELANE CXCL8
196 cardiomyopathy, familial hypertrophic, 2 9.8
197 laryngomalacia 9.8
198 pneumothorax, primary spontaneous 9.8
199 pulmonary hemosiderosis 9.8
200 retinoblastoma 9.8
201 sarcoidosis 1 9.8
202 triiodothyronine receptor auxiliary protein 9.8
203 cleft larynx, posterior 9.8
204 cystic disease of lung 9.8
205 thymoma, familial 9.8
206 dysphasia, familial developmental 9.8
207 panbronchiolitis, diffuse 9.8
208 diabetes mellitus, ketosis-prone 9.8
209 premature ovarian failure 7 9.8
210 hydrops, lactic acidosis, and sideroblastic anemia 9.8
211 deficiency anemia 9.8
212 periventricular nodular heterotopia 9.8
213 pain agnosia 9.8
214 specific language impairment 9.8
215 sensorineural hearing loss 9.8
216 berylliosis 9.8
217 glucose intolerance 9.8
218 spastic diplegia 9.8
219 spastic quadriplegia 9.8
220 pertussis 9.8
221 heart disease 9.8
222 gestational diabetes 9.8
223 patent foramen ovale 9.8
224 toxic shock syndrome 9.8
225 ventricular septal defect 9.8
226 hyperinsulinism 9.8
227 iron metabolism disease 9.8
228 agammaglobulinemia 9.8
229 bilirubin metabolic disorder 9.8
230 glycogen storage disease 9.8
231 acute interstitial pneumonia 9.8
232 lipid metabolism disorder 9.8
233 tracheal stenosis 9.8
234 thymoma 9.8
235 bacterial vaginosis 9.8
236 mastocytosis 9.8
237 placental insufficiency 9.8
238 hyperglycemia 9.8
239 milk allergy 9.8
240 neuromuscular disease 9.8
241 familial retinoblastoma 9.8
242 nephrolithiasis 9.8
243 congestive heart failure 9.8
244 severe combined immunodeficiency 9.8
245 inherited metabolic disorder 9.8
246 polyhydramnios 9.8
247 measles 9.8
248 learning disability 9.8
249 tracheitis 9.8
250 placental abruption 9.8
251 hypereosinophilic syndrome 9.8
252 cantú syndrome and related disorders 9.8
253 flna-related periventricular nodular heterotopia 9.8
254 acute mountain sickness 9.8
255 congenital cytomegalovirus 9.8
256 cor triatriatum 9.8
257 dentinogenesis imperfecta type 2 9.8
258 diaphragmatic flutter 9.8
259 lymphangiectasis 9.8
260 surfactant dysfunction 9.8
261 anoxia 9.8
262 autonomic dysfunction 9.8
263 dysphagia 9.8
264 encephalopathy 9.8
265 rapidly involuting congenital hemangioma 9.8
266 pulmonary interstitial glycogenosis 9.8
267 rare hereditary hemochromatosis 9.8
268 rare pulmonary disease 9.8
269 silicosis 9.8 TIMP1 SCGB1A1 IL1RN CXCL8
270 status asthmaticus 9.8 RNASE3 IL1RN ELANE CXCL8
271 mild pre-eclampsia 9.8 SOD1 FLT1
272 neovascular glaucoma 9.7 FLT1 CXCL8
273 microvascular complications of diabetes 1 9.7 TIMP1 FLT1 CXCL8
274 hellp syndrome 9.6 TIMP1 FLT1 CXCL8
275 dermatitis, atopic 9.6 TIMP1 SELL RNASE3 CXCL8
276 retinal vascular disease 9.6 TXN FLT1 CXCL8
277 skin disease 9.6 SELL RNASE3 FGF7 CXCL8
278 blood group, globoside system 9.5 FLT1 CXCL8
279 eye disease 9.4 RBP4 IL1RN FLT1 CXCL8
280 inflammatory bowel disease 9.3 TIMP1 SELL IL1RN FGF7 ELANE CXCL8
281 rheumatoid arthritis 9.0 TIMP1 SELL IL1RN FLT1 ELANE CXCL8
282 myocardial infarction 8.8 TIMP1 SELL IL1RN FLT1 CXCL8
283 malaria 8.2 TXN TIMP1 SOD1 RNASE3 IL1RN FLT1

Graphical network of the top 20 diseases related to Bronchopulmonary Dysplasia:



Diseases related to Bronchopulmonary Dysplasia

Symptoms & Phenotypes for Bronchopulmonary Dysplasia

Human phenotypes related to Bronchopulmonary Dysplasia:

58 31 (showing 22, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 emphysema 58 31 hallmark (90%) Very frequent (99-80%) HP:0002097
2 cough 58 31 hallmark (90%) Very frequent (99-80%) HP:0012735
3 premature birth 58 31 hallmark (90%) Very frequent (99-80%) HP:0001622
4 respiratory failure requiring assisted ventilation 58 31 hallmark (90%) Very frequent (99-80%) HP:0004887
5 respiratory distress 58 31 hallmark (90%) Very frequent (99-80%) HP:0002098
6 small for gestational age 58 31 hallmark (90%) Very frequent (99-80%) HP:0001518
7 chronic lung disease 58 31 hallmark (90%) Very frequent (99-80%) HP:0006528
8 hyperoxemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0012419
9 sleep disturbance 58 31 frequent (33%) Frequent (79-30%) HP:0002360
10 diaphragmatic paralysis 58 31 frequent (33%) Frequent (79-30%) HP:0006597
11 central apnea 58 31 frequent (33%) Frequent (79-30%) HP:0002871
12 exercise intolerance 58 31 frequent (33%) Frequent (79-30%) HP:0003546
13 right ventricular hypertrophy 58 31 frequent (33%) Frequent (79-30%) HP:0001667
14 right ventricular failure 58 31 frequent (33%) Frequent (79-30%) HP:0001708
15 wheezing 58 31 frequent (33%) Frequent (79-30%) HP:0030828
16 atelectasis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100750
17 tracheobronchomalacia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002786
18 pulmonary sequestration 58 31 occasional (7.5%) Occasional (29-5%) HP:0100632
19 dyspnea 58 Very frequent (99-80%)
20 abnormal lung morphology 58 Very frequent (99-80%)
21 abnormal respiratory system morphology 58 Frequent (79-30%)
22 functional respiratory abnormality 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Bronchopulmonary Dysplasia:

45 (showing 5, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10 ELANE FGF10 FGF7 FLT1 IL1RN RBP4
2 hematopoietic system MP:0005397 9.97 ELANE FGF10 FGF7 FLT1 IL1RN SCGB1A1
3 immune system MP:0005387 9.81 ELANE FGF10 FGF7 FLT1 IL1RN SCGB1A1
4 mortality/aging MP:0010768 9.65 ELANE FGF10 FLT1 IL1RN SCGB1A1 SELL
5 reproductive system MP:0005389 9.23 FGF10 FGF7 FLT1 IL1RN RBP4 SELL

Drugs & Therapeutics for Bronchopulmonary Dysplasia

PubMed Health treatment related to Bronchopulmonary Dysplasia: 62

If your doctor thinks you're going to give birth too early, he or she may give you injections of a corticosteroid medicine. The medicine can speed up surfactant production in your baby. Surfactant is a liquid that coats the inside of the lungs . It helps keep the lungs open so your infant can breathe in air once he or she is born. Corticosteroids also can help your baby's lungs , brain , and kidneys develop more quickly while he or she is in the womb . Premature babies who have very low birth weights also might be given corticosteroids within the first few days of birth. Doctors sometimes prescribe inhaled nitric oxide shortly after birth for babies who have very low birth weights. This treatment can help improve the babies' lung function. These preventive measures may help reduce infants' risk of respiratory distress syndrome (RDS), which can lead to BPD.

Drugs for Bronchopulmonary Dysplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 277, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Procaterol Approved, Investigational Phase 4 72332-33-3 688561
2
Budesonide Approved Phase 4 51333-22-3 63006 5281004
3
Zinc Approved, Investigational Phase 4 7440-66-6 32051
4
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
5
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
6
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
7 Vitamins Phase 4
8 Calciferol Phase 4
9 Adrenergic Agonists Phase 4
10 Antibodies Phase 4
11 Immunoglobulins Phase 4
12 Immunoglobulins, Intravenous Phase 4
13 Lactoferrin Phase 4
14 Vaccines Phase 4
15 Immunologic Factors Phase 4
16 Anti-Infective Agents Phase 4
17 Anti-Bacterial Agents Phase 4
18 Hormone Antagonists Phase 4
19 Hormones Phase 4
20 Anti-Asthmatic Agents Phase 4
21 Bronchodilator Agents Phase 4
22 glucocorticoids Phase 4
23 Anti-Inflammatory Agents Phase 4
24 Antibiotics, Antitubercular Phase 4
25 Gentamicins Phase 4
26 Dermatologic Agents Phase 4
27
Clarithromycin Approved Phase 3 81103-11-9 84029
28
Furosemide Approved, Vet_approved Phase 2, Phase 3 54-31-9 3440
29
Spironolactone Approved Phase 2, Phase 3 52-01-7, 1952-01-7 5833
30
Chlorothiazide Approved, Vet_approved Phase 2, Phase 3 58-94-6 2720
31
Nitric Oxide Approved Phase 3 10102-43-9 145068
32
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
33
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
34
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
35 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
36
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
37
Ibuprofen Approved Phase 2, Phase 3 15687-27-1 3672
38
Calfactant Approved Phase 3 183325-78-2
39
Palivizumab Approved, Investigational Phase 2, Phase 3 188039-54-5
40
Nitrous oxide Approved, Vet_approved Phase 3 10024-97-2 948
41
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
42
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
43
Benzyl alcohol Approved Phase 3 100-51-6 244
44
Ethanol Approved Phase 3 64-17-5 702
45
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
46
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
47
Cysteine Approved, Nutraceutical Phase 2, Phase 3 52-90-4 5862
48
Ergocalciferol Approved, Nutraceutical Phase 2, Phase 3 50-14-6 5280793
49
Vitamin D3 Approved, Nutraceutical Phase 2, Phase 3 67-97-0 5280795 6221
50
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
51
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
52
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
53 Tocotrienol Investigational Phase 3 6829-55-6
54 Mineralocorticoids Phase 2, Phase 3
55 Mineralocorticoid Receptor Antagonists Phase 2, Phase 3
56 Diuretics, Potassium Sparing Phase 2, Phase 3
57 Parenteral Nutrition Solutions Phase 2, Phase 3
58 Amino-acid, glucose, and electrolyte solution Phase 2, Phase 3
59
Beclomethasone Phase 3 4419-39-0 20469
60 Methylprednisolone Acetate Phase 3
61 Analgesics, Non-Narcotic Phase 3
62 Analgesics Phase 3
63 Cyclooxygenase Inhibitors Phase 2, Phase 3
64 Antirheumatic Agents Phase 2, Phase 3
65 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
66
protease inhibitors Phase 3
67 HIV Protease Inhibitors Phase 3
68 BB 1101 Phase 3
69 Anesthetics Phase 3
70 Anesthetics, General Phase 3
71 Anesthetics, Inhalation Phase 3
72 Calcium, Dietary Phase 2, Phase 3
73 Hydrocortisone-17-butyrate Phase 3
74 Antibodies, Monoclonal Phase 3
75 Immunoglobulin G Phase 3
76 Ergocalciferols Phase 2, Phase 3
77 Vitamin D2 Phase 2, Phase 3
78 Antiviral Agents Phase 2, Phase 3
79 Retinol palmitate Phase 3
80 retinol Phase 3
81 Trace Elements Phase 3
82 Nutrients Phase 3
83 Micronutrients Phase 3
84 Tocopherols Phase 3
85 Tocotrienols Phase 3
86 Antidotes Phase 2, Phase 3
87 Expectorants Phase 2, Phase 3
88 N-monoacetylcystine Phase 2, Phase 3
89 Pharmaceutical Solutions Phase 3
90 Antioxidants Phase 2, Phase 3
91 Vasodilator Agents Phase 2, Phase 3
92 Endothelium-Dependent Relaxing Factors Phase 2, Phase 3
93 Protective Agents Phase 2, Phase 3
94 Gastrointestinal Agents Phase 3
95 Antineoplastic Agents, Hormonal Phase 3
96 Antiemetics Phase 3
97 diuretics Phase 3
98 Acidophilus Phase 3
99
Calcium Nutraceutical Phase 2, Phase 3 7440-70-2 271
100
Montelukast Approved Phase 2 158966-92-8 5281040
101
Cefotaxime Approved Phase 2 63527-52-6 5742673 456256
102
Cefoxitin Approved Phase 2 35607-66-0 441199
103
Mecasermin Approved, Investigational Phase 2 68562-41-4
104
Acetaminophen Approved Phase 2 103-90-2 1983
105
Caffeine Approved Phase 2 58-08-2 2519
106
Azithromycin Approved Phase 2 83905-01-5 447043 55185
107
Fludrocortisone Approved, Investigational Phase 2 127-31-1 31378
108 Poractant alfa Approved Phase 2 129069-19-8
109 Beractant Approved Phase 2 108778-82-1
110
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
111
Meclocycline Investigational Phase 2 2013-58-3 5480760
112 Leukotriene Antagonists Phase 2
113 Vitamin B Complex Phase 2
114 Folate Phase 2
115 Vitamin B9 Phase 2
116 Antitubercular Agents Phase 2
117 Insulin, Globin Zinc Phase 2
118 Mitogens Phase 2
119 insulin Phase 2
120 Hematinics Phase 2
121 Epoetin alfa Phase 2 113427-24-0
122 Neurotransmitter Agents Phase 2
123 Phosphodiesterase Inhibitors Phase 2
124 Phosphodiesterase 5 Inhibitors Phase 2
125 Sildenafil Citrate Phase 2 171599-83-0
126 Central Nervous System Stimulants Phase 2
127 Antipyretics Phase 2
128 Tin Fluorides Phase 2
129 Sodium Potassium Chloride Symporter Inhibitors Phase 2
130 Pulmonary Surfactants Phase 2
131 Respiratory System Agents Phase 2
132 Calamus Phase 2
133
Hydrocortisone Approved, Vet_approved Phase 1 50-23-7 5754
134
Hydrocortisone acetate Approved, Vet_approved Phase 1 50-03-3
135
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 1 437-38-7 3345
136
Atropine Approved, Vet_approved Phase 1 51-55-8, 5908-99-6 174174
137 Xenon Experimental Phase 1 7440-63-3
138 Perflubron Investigational Phase 1 423-55-2
139 Hydrocortisone 17-butyrate 21-propionate Phase 1
140 Hydrocortisone hemisuccinate Phase 1
141 Narcotics Phase 1
142 Anti-Arrhythmia Agents Phase 1
143 Analgesics, Opioid Phase 1
144 Cholinergic Agents Phase 1
145 Parasympatholytics Phase 1
146 Anesthetics, Intravenous Phase 1
147 Muscarinic Antagonists Phase 1
148 Mydriatics Phase 1
149 Cholinergic Antagonists Phase 1
150 Anti-Obesity Agents Phase 1
151 Anticonvulsants Phase 1
152 Bromides Phase 1
153
Arginine Investigational, Nutraceutical Phase 1 74-79-3 6322
154
Misoprostol Approved 59122-46-2 5282381
155
Ketamine Approved, Vet_approved 6740-88-1 3821
156
Propofol Approved, Investigational, Vet_approved 2078-54-8 4943